Endovascular Fiducial Placement in Splenic Metastatic Disease as a Novel Option for Radiotherapy: A Case Report

脾转移性疾病血管内植入定位标记物作为放射治疗的新选择:病例报告

阅读:1

Abstract

Splenic metastases are rare but difficult-to-treat entities, especially if they recur after initial surgery or ablation. They are particularly difficult to treat with radiation therapy due to their subdiaphragmatic location and the presence of respiratory excursions. This report describes a case in which an endovascular fiducial placement approach was used to mark the splenic metastasis prior to radiation therapy. We present a 77-year-old male with an extensive history of colorectal metastatic disease. After hemicolectomy, the patient showed metastases - first in the spleen and then in the liver. These were treated with locoregional therapy, including radiofrequency ablation (RFA) for the spleen metastasis and RFA and microwave ablation (MWA) for the liver metastases. Contrast-enhanced computed tomography (CT) imaging, eight years after initial therapy, showed two new liver metastases and a recurrent metastasis in the spleen. Percutaneous ablation of the splenic metastasis was deemed too dangerous because of the subdiaphragmatic location of the spleen and the presence of respiratory motion, and the multidisciplinary tumor board, therefore, opted for radiotherapy. To guide radiotherapy, the interventional radiologist chose to place three microcoil fiducial markers (FMs) around the splenic lesion via an endovascular transradial approach. Radiotherapy was successful, and no recurrence of splenic metastasis has been observed during follow-up. In summary, transradial endovascular FM placement in splenic metastatic disease is technically possible from both an interventional radiological and a radiotherapy standpoint.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。